Canlyniadau Chwilio - Chang, Ching-Fu

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC gan Wu, Chiao-En, Chang, Ching-Fu, Kou-Sheng, Liao, Chiang, Ju, Lee, Shih-Wei, Chiu, Yu-Chi

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study gan Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma gan Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model gan Chang, Ching-Fu, Huang, Pei-Wei, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Hung, Yu-Shin, Chou, Wen-Chi

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI gan Chang, John Wen-Cheng, Huang, Chen-Yang, Fang, Yueh-Fu, Chang, Ching-Fu, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Wu, Chiao-En

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients gan Chang, John Wen‐Cheng, Huang, Chen‐Yang, Fang, Yueh‐Fu, Chang, Ching‐Fu, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Hsu, Ping‐Chih, Wu, Chiao‐En

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy gan Lin, Chia-Hsin, Hung, Tsung-Min, Chang, Yu-Chuan, Hsieh, Chia-Hsun, Shih, Ming-Chieh, Huang, Shih-Ming, Yang, Chan-Keng, Chang, Ching-Fu, Chan, Sheng-Chieh, Yap, Wing-Keen

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy gan Huang, Pei‐Wei, Chang, Ching‐Fu, Hung, Chia‐Yen, Hsueh, Shun‐Wen, Chang, Pei‐Hung, Yeh, Kun‐Yun, Chen, Jen‐Shi, Chen, Yen‐Yang, Lu, Chang‐Hsien, Hung, Yu‐Shin, Chou, Wen‐Chi

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies gan Wu, Chiao-En, Yang, Chan-Keng, Peng, Meng-Ting, Huang, Pei-Wei, Chang, Ching-Fu, Yeh, Kun-Yun, Chen, Chun-Bing, Wang, Chih-Liang, Hsu, Chao-Wei, Chen, I-Wen, Lin, Cheng-Tao, Ueng, Shir-Hwa, Lin, Gigin, Lin, Yu-Fen, Cheng, Chi-Yuan, Chang, John Wen-Cheng

Cael y testun llawn Cael y testun llawn Cael y testun llawn